<DOC>
	<DOCNO>NCT01447355</DOCNO>
	<brief_summary>This pilot phase I trial study vitamin D level skin healthy subject oral supplementation . Chemoprevention use certain drug keep cancer forming . The use cholecalciferol , vitamin D , may keep skin cancer forming .</brief_summary>
	<brief_title>Vitamin D Levels Skin Healthy Subjects After Oral Supplementation</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine high-dose oral cholecalciferol supplementation increase vitamin D receptor ( VDR ) expression keratinocytes photoprotected area healthy subject document insufficient serum level 25-hydroxyvitamin D ( define = &lt; 30.0 ng/mL ) . SECONDARY OBJECTIVES : I . To assess modulation CYP24 expression keratinocytes ( photoprotected photodamaged skin sample ) . II . To assess modulation VDR expression keratinocytes ( photodamaged skin sample ) . III . To assess mechanistic information concern action cholecalciferol supplementation state keratinocytic differentiation assess caspase 14 , loricrin , assessment stratum corneum thickness . IV . To assess safety tolerability high-dose cholecalciferol supplementation patient cohort , include evaluation calcium , phosphate , parathyroid hormone ( PTH ) . V. To assess 25-hydroxyvitamin D level intervention supplementation . TERTIARY OBJECTIVES : I . To assess correspond VDR CYP24 expression benign melanocytic nevus . ( Exploratory ) OUTLINE : Participants receive cholecalciferol orally ( PO ) twice weekly 8-9 week . After completion study treatment , participant follow 10-14 day .</detailed_description>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Documented insufficient serum level 25hydroxyvitamin D = &lt; 30.0 ng/mL At least moderate sundamaged skin midupper right dorsal forearm Karnofsky performance status least 80 % Leukocytes ÃÂ¢ÃÂ¥ 3,000/ÃÃÂ¼L Absolute neutrophil count ÃÂ¢ÃÂ¥ 1,500/ÃÃÂ¼L Platelets ÃÂ¢ÃÂ¥ 100,000/ÃÃÂ¼L Total bilirubin ÃÂ¢ÃÂ¤ 2.0 mg/dL Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamic pyruvic transaminase [ SGPT ] ) = &lt; institutional upper limit normal ( ULN ) Creatinine ÃÂ¢ÃÂ¤ 1.4 mg/dL Serum calcium 8.410.6 mg/dL Parathyroid hormone ( PTH ) : male 8.310.4 mg/dL ; female 8.410.6 mg/dL Women childbearing potential must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ; surgical sterilization ; least one year postmenopausal ) prior study entry duration study participation Skin phototype II III define accord skin response sunlight : Skin phototype II always burn , tan minimally 4560 min unprotected exposure summer sun 121pm Skin phototype III sometimes burn , almost always tan 4560 min unprotected exposure summer sun 121pm Ability understand willingness sign write informed consent Participants may acute chronic hypervitaminosis D hypercalcemia No history increase arterial calcification atherosclerosis , sarcoidosis , histoplasmosis , hyperparathyroidism , lymphoma , kidney disease No current use digoxin ( Lanoxin , digitalis ) , cholestyramine ( Prevalite , Questran ) , colestipol ( Cholestid ) , oral steroid ( prednisone others ) , antacid contain magnesium Participants may receive investigational agent ; complete clinicalintervention trial recently , must 30day period complete previous study enter study No history allergic reaction attribute compound similar chemical biologic composition cholecalciferol , lidocaine , xylocaine No uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant breastfeed woman exclude study No invasive cancer cancer treatment within past five year , except nonmelanoma skin cancer No immunosuppression virtue medication disease ; include acquire immune deficiency syndrome ( AIDS ) patient , subject take oral prednisone , subject immunosuppressants/immunomodulators ( cyclosporine , chemotherapeutic agent , biologic therapy ) , determine examine investigator/coinvestigator Unwilling unable refrain take herbal medicine abovestandard vitamin mineral study A standard daily multivitamin/mineral supplement acceptable contains ÃÃÂ¢ÃÃÂ¤ 600 IU vitamin D , ÃÃÂ¢ÃÃÂ¤ recommend dietary allowance ( RDA ) calcium , subject take stable dose least 30 day Potential subject take abovestandard dos supplement may reconsider participation 30day washout period No participant use tan bed method promote suntanning within 6 month study entry ; practice may undertake participation study Participants unwilling minimize exposure sunlight apply sunscreen/sunblock wear clothing shield skin , outdoor activity , enrol study Individuals receive concurrent topical therapy retinoids , steroid , 5fluorouracil , Levulan , Vaniqa ( eflornithine ) , Solaraze , Imiquimod ( AldaraÃÃÃÂ® ) within 30 day prior study enrollment exclude ; subject may reconsider eligibility 30 day last treatment Individuals treatment basal cell carcinoma squamous cell carcinoma skin right forearm within six month prior evaluation study eligible ; subject encourage return reevaluation sixmonth period</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>